Cabaletta Bio EBITDA 2019-2025 | CABA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cabaletta Bio ebitda from 2019 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cabaletta Bio ebitda from 2019 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$249.7B
Amgen (AMGN)	$159.6B
Gilead Sciences (GILD)	$147.3B
Vertex Pharmaceuticals (VRTX)	$101.1B
Bristol Myers Squibb (BMY)	$98.2B
GSK (GSK)	$81.6B
CSL (CSLLY)	$68.5B
Regeneron Pharmaceuticals (REGN)	$62.6B
Alnylam Pharmaceuticals (ALNY)	$60.1B
Argenex SE (ARGX)	$40.5B
Insmed (INSM)	$27.4B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$21.5B
Biogen (BIIB)	$20.4B
Incyte (INCY)	$16.8B
Genmab (GNMSF)	$15.9B
Illumina (ILMN)	$15.5B
Genmab (GMAB)	$15.4B
Ascendis Pharma (ASND)	$11.8B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.9B
Moderna (MRNA)	$10.5B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Halozyme Therapeutics (HALO)	$8.3B
Roivant Sciences (ROIV)	$8B